Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma | MicrobiomeTrials← Back to trialsNCT06192797
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-06-04Est. Completion: 2028-06-30
Enrollment target: 36 participants Locations- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Other microbiome trials you might be interested in
FGFR2 Gene Fusion/RearrangementOther Solid Tumors, Adult
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with pr…
Phoenix, United StatesEst. completion Sep 2027
Cancer Harboring BRAF AlterationsHGGLGGSolid Tumors
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF a…
Beverly Hills, United StatesEst. completion Dec 31, 2027
Biliary Tract Cancer (BTC)
This study is a prospective, multicenter, single-arm, open-label Phase II clinical trial, planned to enroll 30 patients …
Tianjin, ChinaEst. completion Oct 2027